Generation of a bovine cell line for gene engineering using an HIV-1-based lentiviral vector

Nanami Morizako¹, Erika P. Butlertanaka², Yuri L. Tanaka¹, Honoka Shibata¹, Tamaki Okabayashi¹,²,³, Hirohisa Mekata² & Akatsuki Saito¹,²,³*

Human immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors are indispensable tools for gene engineering in mammalian cells. Conversely, lentiviral vector transduction is severely inhibited in bovine cells. Previous studies demonstrated that this inhibition is caused by the anti-lentiviral host factor tripartite motif containing 5 (TRIM5), which targets incoming HIV-1 virions by interacting with the viral capsid. In this study, we investigated several methods for overcoming the limited applicability of lentiviral vectors in bovine cells. First, we demonstrated that the SPRY domain of bovine TRIM5 is the major determinant of anti-viral activity. Second, we found that mutations that allow the capsid to evade rhesus macaque TRIM5α minimally rescued HIV-1 infectivity in bovine-derived MDBK cells. Third, we found that cyclosporine A, which relieves the inhibition of HIV-1 infection in monkey cells, significantly rescued the impaired HIV-1 infectivity in MDBK cells. Lastly, we successfully generated a bovine cell line lacking intact TRIM5 using the CRISPR/Cas9 technique. This TRIM5 knockout cell line displayed significantly higher susceptibility to an HIV-1-based lentiviral vector. In conclusion, our findings provide a promising gene engineering strategy for bovine cells, thereby contributing to innovations in agriculture and improvements in animal health.

Although mouse leukemia virus (MLV)-based retroviral vectors are powerful tools for gene engineering in mammalian cells, the vectors require cellular mitosis for efficient infection. Therefore, it is technically challenging to use retroviral vectors for non-dividing cells such as neural cells, macrophages, and dendritic cells. By contrast, human immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors efficiently infect both dividing and non-dividing cells. A previous study demonstrated that cone-shaped HIV-1 capsid (CA) proteins translocate through nuclear pore complexes. Thus, HIV-1-based lentiviral vector has been widely used in broad fields including gene therapy in humans and gene modification of animals. However, transduction by HIV-1-based lentiviral vectors is severely inhibited in bovine cells during the step of reverse transcription, hampering this strategy. This inhibition is caused by an anti-HIV-1 host factor tripartite motif containing 5 (TRIM5) in bovine cells, which targets incoming HIV-1 virions by interacting with viral CA. TRIM5α was initially identified as an anti-HIV-1 host factor in rhesus macaque (RM) cells. Mammalian TRIM5 consists of a RING domain, B-box domain, Coiled-coil domain, and SPRY (B30.2) domain. The RING domain is a class E3 ubiquitin ligase that is involved in the proteasome-mediated viral CA degradation. The B-box and Coiled-coil domains are responsible for the dimerization and higher-order association of TRIM5 protein. The SPRY domain is involved in direct interaction with viral CA. Importantly, TRIM5 gene evolved under positive selection, suggesting that mammalian TRIM5 has been the frontline anti-retroviral host factor.

In this study, we investigated multiple methods for overcoming the limited applicability of HIV-1-based lentiviral vectors in bovine cells. First, we demonstrated that the SPRY domain of bovine TRIM5 was the major determinant of anti-viral activity. Second, we found that CA mutations that confer resistance to RM TRIM5α or owl monkey TRIM5α failed to rescue HIV-1 infectivity in bovine-derived Madin–Darby bovine kidney (MDBK) cells. Third, we demonstrated that cyclosporine A (CsA), which relieves the inhibition of HIV-1 infection in monkey cells, could rescue the impaired HIV-1 infectivity in MDBK cells. Finally, we generated a MDBK cell line lacking intact TRIM5 using the CRISPR/Cas9 method. TRIM5 knockout cells exhibited significantly greater susceptibility to HIV-1 infection. Furthermore, we demonstrated that an HIV-1 vector efficiently infected cell cycle-arrested TRIM5-knockout cells. Overall, our methods developed in this study provide a
promising strategy for gene engineering in bovine cells, contributing to innovations in agriculture and improvements in animal health.

Results

**TRIM5 depletion sensitized bovine-derived MDBK cells to HIV-1 infection.** To investigate the impact of bovine TRIM5 on inhibition of HIV-1 infection in bovine cells, we depleted TRIM5 in MDBK cells via siRNA transfection. We used siRNA targeting bovine TRIM5 as previously described. Prior to testing the anti-viral activity, the efficiency of TRIM5 depletion was evaluated by quantitative real-time reverse transcription (qRT)-PCR. The results in Fig. 1a illustrate that siRNA transfection decreased TRIM5 mRNA levels by 75% versus those in normal MDBK cells. To test the effect of TRIM5 depletion, the cells were infected with an HIV-1-based vector encoding ZsGreen reporter protein. Our flow cytometric analysis revealed that the infectivity in TRIM5-depleted MDBK cells was approximately tenfold higher than that in mock-transfected MDBK cells, demonstrating that bovine TRIM5 was a major anti-HIV-1 host factor in MDBK cells.

The SPRY domain is the determinant for the anti-viral activity of bovine TRIM5. We demonstrated that bovine TRIM5 strongly inhibited HIV-1 infection (Fig. 1b). By contrast, previous studies demonstrated that HIV-1 evades restriction by human TRIM5α. The identity between bovine TRIM5 and human TRIM5α was 56.0% (calculated on the website of SIM—Alignment Tool for protein sequences [https://web.expasy.org/sim/], Fig. 2a). To identify the TRIM5 domain that determines the species specificity, we generated a series of chimeric TRIM5 molecules between bovine TRIM5 and human TRIM5α (Fig. 2b). Whereas the molecule containing the human TRIM5α-derived RING, B-box, and Coiled-coil domains (RBCC) and bovine-derived SPRY domain was termed “HuBo,” chimeric TRIM5 containing a bovine TRIM5-derived RBCC domain and a human TRIM5α-derived SPRY domain was termed “BoHu.” Furthermore, we generated a truncated form of bovine TRIM5 lacking the SPRY domain (termed “delSPRY”). We used a TRIM5-null Crandell–Rees feline kidney (CRFK) cell line to generate cells stably expressing these molecules. After confirming the expression of each TRIM5 molecule by Western blotting (Fig. 2c and Supplemental Fig. 1), the cells were infected with HIV-1 vectors encoding luciferase reporter protein. Consistent with the observation in MDBK cells (Fig. 1b), HIV-1 infection was significantly blocked in CRFK cells expressing bovine TRIM5 (blue) (Fig. 3a). Conversely, human TRIM5α (purple) slightly blocked HIV-1 infection, reproducing the previous findings. In CRFK cells expressing chimeric molecules, although viral infection was significantly suppressed in CRFK cells expressing HuBo (red), infection was not blocked in CRFK cells expressing BoHu (green). Furthermore, CRFK cells expressing delSPRY (orange) displayed significantly weaker inhibition than those expressing bovine TRIM5 (blue). These observations suggest that the SPRY domain of bovine TRIM5 is the major determinant of the TRIM5-mediated inhibition of HIV-1 infection.

In addition to HIV-1 vectors, the anti-viral activity of chimeric TRIM5 molecules against other lentiviruses including simian immunodeficiency virus (SIVmac, Fig. 3b), feline immunodeficiency virus (FIV, Fig. 3c), and equine infectious anemia virus (EIAV, Fig. 3d) was examined. Whereas TRIM5 molecules containing bovine...
Figure 2. Generation of CRFK cells expressing chimeric TRIM5 proteins. (a) Alignment of bovine TRIM5 and human TRIM5α. The protein sequences of bovine TRIM5 and human TRIM5α were aligned using MEGA X. The domains of TRIM5 were indicated in yellow (RING domain), green (B-box domain), blue (Coiled-coil domain), and pink (SPRY domain). (b) Schematic representation of chimeric TRIM5 molecules generated in this study. The chimera TRIM5 molecule "HuBo" consists of the RING, B-box, and Coiled-coil (RBCC) domains of human TRIM5α and the SPRY domain of bovine TRIM5. The chimeric TRIM5 molecule "BoHu" consists of the RBCC domain of bovine TRIM5 and SPRY domain of human TRIM5α. A truncated version of bovine TRIM5 lacking the SPRY domain was termed "delSPRY." (c) Expression of each HA-tagged TRIM5 protein in CRFK cells was determined using Western blotting. The cellular lysate of unmodified CRFK cells was used as a negative control (empty).
Figure 3. The SPRY domain of bovine TRIM5 is the determinant of anti-lentiviral activity. (a) (left) CRFK cells expressing TRIM5 proteins were infected with an HIV-1 vector encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. (right) Relative infectivity was calculated using the values in the left panel. (b) (left) CRFK cells expressing TRIM5 proteins were infected with an SIVmac vector encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. (right) Relative infectivity was calculated using the values in the left panel. (c) (left) CRFK cells expressing TRIM5 proteins were infected with an FIV vector encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. (right) Relative infectivity was calculated using the values in the left panel. (d) (left) CRFK cells expressing TRIM5 proteins were infected with an EIAV vector encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. (right) Relative infectivity was calculated using the values in the left panel. (e) (left) CRFK cells expressing TRIM5 proteins were infected with an MLV vector encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. (right) Relative infectivity was calculated using the values in the left panel.
SPRY (blue and red) suppressed infection by SIVmac and FIV (Fig. 3b–c), those carrying human SPRY domain (green and purple) minimally blocked these viruses. Consistent with previous reports⁶,⁷,²², both bovine TRIM5 and human TRIM5α blocked EIAV infection (Fig. 3d). Interestingly, both chimeric molecules (red and green) lost anti-EIAV activity. To test the specificity of inhibition by these TRIM5 molecules, the infectivity of MLV was examined in these cells. We observed comparable infectivity of MLV on all cells (Fig. 3e), supporting that the obtained results indicated specific inhibition by TRIM5 molecules. Collectively, bovine TRIM5 exhibits broad anti-lentiviral activity, and the SPRY domain is the major determinant of its anti-viral activity.

**Mutations in CA did not rescue HIV-1 infection in MDBK cells.** Previous research demonstrated that viral CA of incoming HIV-1 particles is the interface recognized by mammalian TRIM5 molecules [reviewed in ²³]. Therefore, mutations in CA can alter the susceptibility to TRIM5-mediated inhibition. Previous studies demonstrated that long-term passaging of wild-type (WT) HIV-1 in a cell line expressing RM TRIM5α resulted in the selection of the V86M or H87Q mutation in the cyclophilin A (CypA)-binding loop of CA²⁴,²⁵. Importantly, these mutations partially rescued restriction by RM TRIM5α²⁵,²⁶. To investigate whether V86M and H87Q CA mutants could evade inhibition by bovine TRIM5, we used owl monkey kidney (OMK) cells, RM-derived FRhK-4 cells, and MDBK cells for infection experiments because HIV-1 infection was blocked in these cell lines. The result demonstrated that both V86M and H87Q exhibited higher infectivity than WT HIV-1 in OMK cells (Fig. 4). In FRhK-4 cells, the H87Q mutation partially rescued HIV-1 infection. However, neither V86M nor H87Q rescued HIV-1 infection in MDBK cells. Collectively, CA mutations that confer partial resistance to HIV-1 in monkey cells failed to rescue HIV-1 infectivity in MDBK cells.

**CsA treatment significantly rescued HIV-1 infectivity in MDBK cells.** Previous studies demonstrated that cellular Cyclophilin A (CypA) is associated with TRIM5α-mediated inhibition⁶,¹⁷,²⁷. In human CD4+ T cells, CypA protects HIV-1 from human TRIM5α²⁸. Conversely, CypA sensitizes HIV-1 to TRIM5α in monkey cells²⁹; thus, interruption of the CA–CypA interaction rescued HIV-1 infectivity in monkey cells. Based on these observations, we tested whether the disruption of CypA–CA binding rescues HIV-1 infection.
in bovine cells. To this end, we used two methods. We used a CA mutant, RGDA/Q112D + Q4R, possessing six mutations (Q4R, H87R, A88G, P90D, P93A, and Q112D) in CA29. We previously demonstrated that the RGDA/Q112D + Q4R mutant completely lost CypA binding. Furthermore, this CA mutant had higher infectivity than the WT virus in human-derived Jurkat cells. OMK, Lenti-X 293T, and MDBK cells were infected with WT or RGDA/Q112D + Q4R virus. The RGDA/Q112D + Q4R virus had an eightfold higher infectivity than the WT virus in OMK cells (Fig. 5a). This result can be explained by the fact that OMK cells express a TRIMCyp fusion protein between TRIM5α and CypA16,30. Conversely, the infectivity of RGDA/Q112D + Q4R was significantly lower than WT in Lenti-X 293T and MDBK cells. This suggests that although the RGDA/Q112D + Q4R mutations conferred resistance to TRIMCyp in OMK cells, these mutations sensitized HIV-1 to restriction factors in human and bovine cells.

It has been demonstrated that the inhibition of HIV-1 infection in OMK cells was canceled by treatment with Cyclosporin A (CsA), which specifically disrupts the CypA–CA interaction16,30,31. Based on this finding, we tested whether CsA treatment rescued HIV-1 infectivity in MDBK cells. OMK, Lenti-X 293T, and MDBK cells were infected with an HIV-1 vector in the presence or absence of CsA. The infectivity of the HIV-1 vector was increased by approximately 100-fold by CsA treatment in OMK cells (Fig. 5b), reproducing previous findings16,30,31. Contrarily, CsA treatment significantly decreased HIV-1 infectivity in Lenti-X 293T cells. Notably, HIV-1 infectivity was threefold higher in CsA-treated MDBK cells than in control cells. This suggests that host factors targeted by CsA, at least in part, are involved in the restriction of HIV-1 in MDBK cells. Collectively, CsA treatment significantly rescued HIV-1 infection in MDBK cells.

Knockout of bovine TRIM5 significantly enhanced HIV-1 infection on MDBK cells. Based on the aforementioned findings, we next knocked out TRIM5 in MDBK cells. First, we screened five candidate single-guide RNA (sgRNA) constructs. We PCR-amplified a 796-base pair (bp) fragment covering the target sequences of the five sgRNAs. An in vitro cleavage assay demonstrated that sgRNA #4 cleaved the PCR fragment encoding bovine TRIM5 with the highest efficiency (Fig. 6a). We therefore ligated this sgRNA sequence to the PX459 vector to generate PX459-TRIM5-sgRNA#4. Then, MDBK cells were transduced with PX459-TRIM5-sgRNA#4. After selection and single-cell cloning, each clone was evaluated by infection with HIV-1 vector encoding luciferase reporter protein. As presented in Fig. 6b, MDBK TRIM5-knockout cells (clones #4–6) exhibited approximately eightfold higher infectivity than the original MDBK cells. We next examined the genomic sequence of MDBK TRIM5-knockout cells (clones #4–6). The result demonstrated that this clone featured the deletion of one nucleotide, resulting in the emergence of an early stop codon (Fig. 6c).

Next, we examined whether an HIV-1-based lentiviral vector could infect non-dividing cells. To this end, MDBK TRIM5-knockout cells (clones #4–6) were treated with aphidicin (Aph) to arrest the cell cycle and infected with HIV-1 or MLV vectors. Consistent with previous observations12, the MLV vector failed to infect non-dividing cells (Fig. 7, right). By contrast, the HIV-1 vector efficiently infected both dividing and non-dividing cells (Fig. 7, left).
Figure 5. CsA treatment significantly enhanced HIV-1 infectivity in MDBK cells. (a) OMK (left), Lenti-X 293T (center), and MDBK cells (right) were infected with the WT virus or RGDA/Q112D + Q4R CA mutant encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. Relative infectivity was calculated using the values of the WT virus. (b) OMK (left), Lenti-X 293T (center), and MDBK cells (right) were infected with HIV-1 vectors encoding luciferase reporter protein in the presence of DMSO or 2 µM Cyclosporin A (CsA). The infectivity was determined as RLU 2 days after infection. The relative infectivity was calculated according to the control values. The results are presented as the mean and standard deviation of triplicate measurements from one assay, and they are representative of at least three independent experiments. Differences were examined by a two-tailed, unpaired Student’s t-test. ****p < 0.0001, ***p < 0.001, **p < 0.01.
Figure 6. Knockout of TRIM5 sensitized MDBK cells to HIV-1 infection. (a) Genomic DNA of MDBK cells encoding TRIM5 was amplified using PCR. The amplicon was mixed with sgRNA and Cas9 protein to determine the cleavage efficiency. The results of electrophoresis are presented. “M” denotes marker, and “(-)” indicates an amplicon mixed with only Cas9 protein. (b) MDBK TRIM5-knockout (k/o) cells (clones #4–6) or normal MDBK cells (Control) were infected with HIV-1 vectors encoding luciferase reporter protein. The infectivity was determined as relative light units (RLU) 2 days after infection. Relative infectivity was calculated using the control values. The results are presented as the mean and standard deviation of triplicate measurements from one assay, and they are representative of at least three independent experiments. Differences were examined by a two-tailed, unpaired Student's t-test. ***p < 0.001. (c) Genomic DNA of MDBK TRIM5 k/o cells (clones #4–6) was amplified using PCR. The amplicon was subjected to sequencing to identify gene editing. The raw data on 4Peaks software (Nucleobytes) are presented.
Collectively, gene disruption of TRIM5 is a feasible method for transducing bovine cells including non-dividing cells with an HIV-1-based lentiviral vector.

**Discussion**

In this study, we utilized multiple approaches to overcome the limited applicability of HIV-1-based lentiviral vector in bovine cells. First, we observed that bovine TRIM5 is the major anti-HIV-1 host factor in MDBK cells. We revealed that the SPRY domain determined the broad anti-lentiviral activity. Second, we found that CA mutants that evade monkey-derived TRIM5 failed to rescue HIV-1 infectivity in MDBK cells. Third, we demonstrated that HIV-1 infection was significantly enhanced by CsA in MDBK cells. Lastly, TRIM5-knockout MDBK cells generated in this study displayed significantly higher susceptibility to HIV-1 infection.

Viral vectors are indispensable for broad applications including gene therapy, cancer therapy, and vaccine development. In particular, HIV-1-based lentiviral vectors have a series of advantages compared to other viral vectors. First, because the viral genome integrates into the host genome, the transduced gene can be stably expressed in the host. Second, because HIV-1-based lentiviral vectors can transduce non-dividing cells, they can be applied to broad target cells including neural cells and macrophages. In particular, lentiviral vectors can transduce dendritic cells, leading to the efficient induction of both humoral and cellular immunity to antigens. Therefore, veterinary and agricultural fields might require the application of HIV-1-based lentiviral vectors. Considering the possible application of lentiviral vectors in these fields, stable expression of viral receptors in bovine cells can improve the efficiency of virus isolation from clinical samples, contributing to the better diagnosis and the further understanding of disease pathogenesis.

Consistent with previous studies, HIV-1 infection was mainly blocked by bovine TRIM5 in MDBK cells. In addition, bovine TRIM5 suppressed broad lentiviruses including HIV-1, SIVmac, FIV, and EIAV. It is tempting to consider why bovine TRIM5 has such a broad anti-lentiviral spectrum. It had remained unclear which domain of bovine TRIM5 is the determinant for anti-viral activity. In this study, we addressed this point using chimeric molecules between human TRIM5α and bovine TRIM5. We concluded that the SPRY domain of bovine TRIM5 was the major determinant for the species-specific inhibition. It is tempting to elucidate which motif(s) or residue(s) in the SPRY domain determined this specificity in a future study.

Based on previous findings that mutations in CA can change the sensitivity to TRIM5α/TRIMCyp, we tested whether V86M and H87Q mutations rescued HIV-1 infectivity in MDBK cells. Although the H87Q mutation enhanced HIV-1 infectivity in OMK cells and FRhK-4 cells, the mutation failed to rescue HIV-1 infectivity in...
MDBCk cells. This result suggests that the recognition of HIV-1 CA by RM TRIM5α differs from that by bovine TRIM5.

Next, we tested whether modulating CA–CypA binding could rescue HIV-1 infectivity in MDBCk cells. We found that the CypA binding-deficient CA mutant RGDA/Q112D + Q4R virus exhibited enhanced infectivity in OMk cells. By contrast, the mutations decreased HIV-1 infectivity in Lenti-X 293T cells. Because Kim et al. demonstrated that CypA protects HIV-1 against human TRIM5α-mediated inhibition35, our result might reflect this phenomenon. In MDBCk cells, the infectivity of the RGDA/Q112D + Q4R mutant was significantly lower than that of the WT virus, suggesting that these mutations sensitized HIV-1 to bovine TRIM5 or other anti-HIV-1 host factors. We hypothesized that CsA treatment would exert a similar or identical effect as RGDA/Q112D + Q4R mutations. This was true for infection in OMk and Lenti-X 293T cells. However, HIV-1 vector infectivity was threefold higher in CsA-treated MDBCk cells than in control cells. This result suggests that CsA relieved the inhibitory effects in MDBCk cells. Because CsA targets several Cyps, the molecular mechanism of enhancement by CsA should be addressed in a future study. Nevertheless, our finding suggests that CsA treatment is useful when bovine cells need to be transduced by an HIV-1-based lentivector.

Finally, we knocked out TRIM5 from MDBCk cells. The effect of TRIM5 knockout was obvious, as HIV-1 infectivity was approximately eightfold higher in TRIM5-knockout cells. Considering the future use of lentivector vectors in bovine-derived non-dividing cells, we tested the infectivity of HIV-1 and MLV vectors in TRIM5-knockout cells. Although MLV vectors failed to infect non-dividing cells, HIV-1 vectors efficiently infected both dividing and non-dividing cells. This result supports our idea that the application of lentivector vectors will facilitate gene engineering in bovine cells.

In conclusion, the methods developed in this study provide a promising strategy for gene engineering in bovine cells, contributing to innovations in agriculture and improvements in animal health.

Materials and methods
Plasmids. The following plasmids were obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: SIV Packaging Construct (SIV3 +, Cat# ARP-13456) and SIV LTR Luciferase mCherry Reporter Vector (Cat# ARP-13455), both of which were provided by Dr. Tom Hope. The pDON-5 Neo DNA plasmid (Cat# 3657) and pLV SIN-CMV Hyg-ZsGreen plasmid (Cat# 6182) were purchased from Takara. The following plasmids were kind gifts from Dr. Kenzo Tokunaga: pSAX2-IN/HiBiT plasmid36 and pWPI-Luc2 plasmid36, pLionII (Cat# 1730; http://n2t.net/addgene:1730; RRID: Addgene_1730) and pCPRD Env (Cat# 1732; http://n2t.net/addgene:1732; RRID: Addgene_1732) were gifts from Dr. Garry Nolan. pMD2.G was a gift from Dr. Didier Trono (Cat# 12259; http://n2t.net/addgene:12259; RRID: Addgene_12259). pEIAV-SIN6.1 CGFPW (Cat# 44171; http://n2t.net/addgene:44171; RRID: Addgene_44171) and pEV53D (Cat# 44168; http://n2t.net/addgene:44168; RRID: Addgene_44168) were gifts from Dr. John Olsen. pSpCas9(BB)-2A-Puro (PX459) V2.0 was a gift from Dr. Feng Zhang (Addgene plasmid # 62988; http://n2t.net/addgene:62988; RRID: Addgene_62988). To generate a luciferase-encoding FIV vector, a cDNA encoding luciferase 2 (luc2) was ligated to the pLionII plasmid. To generate a luciferase-encoding ELAV vector, cDNA encoding EGFP in the pEIAV-SIN6.1 CGFPW plasmid was swapped with cDNA encoding luc2.

Cell culture. Lenti-X 293T (TaKaRa, Cat# Z2180N), OMK (American Type Culture Collection (ATCC), Cat# CRL-1556), HeLa (ATCC, Cat# CCL-2), FRhK-4 (ATCC, Cat# CRL-1688), MDBCk (Japanese Collection of Research Bioresources Cell Bank (JCRB), Cat# IFO50014), and CRFK cells (JCRB, Cat# JCRB9035) were cultured in Dulbecco’s modified Eagle’s medium (Nacalai Tesque, Cat# 08458–16) supplemented with 10% fetal bovine serum and 1× penicillin–streptomycin (Nacalai Tesque, Cat# 09367–34).

Rescue of reporter viruses. To rescue an HIV-1–based lentivector, Lenti-X 293T cells were co-transfected with the pSAX2-IN/HiBiT, pLV SIN-CMV Hyg-ZsGreen or pWPI-Luc2 plasmids using TransIT-293 Transfection Reagent (TaKaRa, Cat# Z2180N) in Opti-MEM I Reduced Serum Medium (Thermo Fisher Scientific, Cat# 31985062). To rescue an SIVmac-based lentivector, Lenti-X 293T cells were co-transfected with the pCPRD Env, pLionII-luc2, and pMD2.G plasmids. To rescue an ELAV-based lentivector, Lenti-X 293T cells were co-transfected with the pCPRD Env, pLionII-luc2, and pMD2.G plasmids. To rescue an MLV-based retroviral vector, Lenti-X 293T cells were co-transfected with pGP, pDON-5 Neo-luc2, and pMD2.G plasmids. The supernatant was collected and filtered 2 days after transfection.

Virus infection. CRFK, OMK, FRhK-4, and MDBCk cells were plated on a 96-well plate at 1×10^4 cells per well. Lenti-X 293T cells were plated on a 96-well plate at 3×10^4 cells per well. After overnight culture, the cells were infected with the reporter viruses. In case of the infection of non-dividing cells, MDBCk cells were plated on a 96-well plate at 2.5×10^4 cells per well and treated with 1 μg/mL Aphidicolin (Aph) (WAKO, Cat# 011–09811) for 24 h prior to infection. As needed, cells were cultured in the presence of 2 μM Cyclosporin A (CsA) (Selleck, Cat# S2286). For infection with HIV-1 CA mutants, the cells were infected with equal amount of viruses (861 HiBiT values per well). The HiBiT value was measured using the Nano Glo HiBiT Lytic Detection System (Promega, Cat# N3040) as described previously36. For ZsGreen-encoding virus, ZsGreen positivity in the infected cells was measured 2 days after infection using an Attune NxT Flow Cytometer (Thermo Fisher Scientific) and a CytKick Autosampler (Thermo Fisher Scientific). For luciferase-encoding virus, the infected cells were lysed 2 days after infection with a Bright-Glo
Luciferase Assay System (Promega, Cat# E2620) and the luminescent signal was measured using a GloMax Explorer Multimode Microplate Reader (Promega).

**TRIM5 depletion.** To deplete TRIM5, MDBK cells adjusted to 5 × 10^6 cells per well in a 6-well plate were transfected with siRNA targeting bovine TRIM5 (5′-AGAAUGACUGGUGCCAGA-3′) (synthesized by Sigma-Aldrich) or scrambled negative control siRNA (Thermo Fisher Scientific, Cat# 465372) with TransIT-X2 Dynamic Delivery System (TaKaRa, Cat# V6100) in Opti-MEM. After overnight culture, the cells were re-plated on a new 96-well plate at 1 × 10^4 cells per well. The cells were cultured again overnight and infected with ZsGreen-encoding lentiviruses. Two days after infection, the ZsGreen-positive rate was measured using an Attune NxT Flow Cytometer.

**Quantification of mRNA levels in depleted cells.** MDBK cells transfected with siRNA were plated on a 96-well plate at 1 × 10^4 cells per well. After overnight culture, mRNA expression was quantified by qRT-PCR using the CellAmp Direct RNA Prep Kit for RT-PCR (Real Time) (TaKaRa, Cat# 3732). One Step TB Green Premix PLUS RT-PCR Kit (Perfect Real Time) (TaKaRa, Cat# RR906A), and primer pairs for bovine TRIM5 (5′-CCATTGGCAAGGAATAAGAAT-3′ and 5′-CTCGAACACCTCCTCTGTGTC-3′) and Gapdh (5′-GGC ATACTCAACTCTTATCTGTGA-3′ and 5′-TGGTACAGGAAATAGACCTTGAC-3′). qRT-PCR was performed using the QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific), and the Ct values of TRIM5 were normalized to the mean values obtained using Gapdh as a housekeeping gene (ΔΔCt method).

**Construction of plasmids for expressing TRIM5 molecules.** Total RNA was extracted from MDBK and HeLa cells using an RNase Mini Kit (Qiagen, Cat# 74104) and QiAshredder (Qiagen, Cat# 79656). cDNA was synthesized using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific, Cat# 18090050) and primers bT5-F (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′ and bT5-R for bovine TRIM5 cDNA or hT5-F (5′-TGGGCGGGGGCGGGCGGCGGACACGTGCTTGGTGAGAAGACATG-3′) and hT5-R for bovine TRIM5α cDNA. The PCR protocol consisted of 30 cycles of 98 °C for 10 s, 60 °C for 15 s, and 72 °C for 1 min, followed by 72 °C for 7 min. The amplified fragments were ligated into pDON-5 Neo vector (TaKaRa, Cat# 3657), which was pre-linearized with NotI-HF (NEB, Cat# R3189L) and BamHI-HF (NEB, Cat# R3136L) using an In-Fusion HD Cloning Kit (TaKaRa, Cat# Z9633N). Then, the plasmid was amplified using NEB 5-alpha F (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′ and 5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) for total RNA extracted from MDBK cells or hT5-R (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) and hT5-F for human TRIM5α cDNA. The PCR protocol consisted of 30 cycles of 98 °C for 10 s, 60 °C for 15 s, and 72 °C for 1 min. The amplified fragments were ligated into a pDON-5 Neo vector and the plasmids were extracted with PureYield Plasmid Miniprep System (Promega, Cat# A1222). The sequences of bovine TRIM5 mRNA (Accession# LC727630) and human TRIM5α mRNA (Accession# LC727631) were deposited in the GenBank.

To generate a chimeric molecule termed BoHu, we used bT5-F and BoHu-R (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) to amplify the bovine RBCC domain and HuBo-F (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) for the 5′ end of the hT5-F (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) and hT5-R for human TRIM5α cDNA. The PCR protocol consisted of 30 cycles of 98 °C for 10 s, 60 °C for 15 s, and 72 °C for 1 min. The amplified fragments were ligated into pDON-5 Neo vector and the plasmids were extracted with PureYield Plasmid Miniprep System (Promega, Cat# A1222). The sequences of bovine TRIM5 mRNA (Accession# LC727630) and human TRIM5α mRNA (Accession# LC727631) were deposited in the GenBank.

To generate the chimeric molecule termed BoHu, we used bT5-F and BoHu-R (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) to amplify the bovine RBCC domain and HuBo-F (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) and hT5-R for human TRIM5α cDNA. The PCR protocol consisted of 30 cycles of 98 °C for 10 s, 60 °C for 15 s, and 72 °C for 1 min. The amplified fragments were ligated into a pDON-5 Neo vector and the plasmids were extracted with PureYield Plasmid Miniprep System (Promega, Cat# A1222). The sequences of bovine TRIM5 mRNA (Accession# LC727630) and human TRIM5α mRNA (Accession# LC727631) were deposited in the GenBank.

To generate a chimeric molecule termed BoHu, we used bT5-F and BoHu-R (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) to amplify the bovine RBCC domain and HuBo-F (5′-AACGTCGACGGGATCCAGATATTAATAGGAGTCTGAGAACCAGATAT-3′) and hT5-R for human TRIM5α cDNA. The PCR protocol consisted of 30 cycles of 98 °C for 10 s, 60 °C for 15 s, and 72 °C for 1 min. The amplified fragments were ligated into a pDON-5 Neo vector and the plasmids were extracted with PureYield Plasmid Miniprep System (Promega, Cat# A1222). The sequences of bovine TRIM5 mRNA (Accession# LC727630) and human TRIM5α mRNA (Accession# LC727631) were deposited in the GenBank.
Expression level of HA-tagged TRIM5 in CRFK cells was confirmed by Western blotting using an anti-HA Tag Cat# B0008) containing 2% β-mercaptoethanol (Bio-Rad, Cat# 1610710) and incubated at 70 °C for 10 min. HRP antibody (Sigma-Aldrich, Cat# A3854-200UL, × 20,000) as a loading control. Chemiluminescence was detected using Western BLoT Ultra Sensitive HRP Substrate (TaKaRa, Cat# T7104A) according to the manufacturer’s instructions. Bands were visualized using an iBright FL1500 imaging system (Thermo Fisher Scientific).

Stripping Solution Strong (Nacalai Tesque, Cat# 05677–65), the membrane was re-probed with an anti-β-Actin–Taq (2002) (Life Technologies, Cat# A22288) as an internal control. Chemiluminescence was detected using Western BLoT Ultra Sensitive HRP Substrate (TaKaRa, Cat# T7104A) according to the manufacturer’s instructions. Bands were visualized using an iBright FL1500 imaging system (Thermo Fisher Scientific). The band intensity was quantified using iBright analysis software (Thermo Fisher Scientific).

Calculation of the identity between bovine TRIM5 and human TRIM5α proteins. The protein sequences of bovine TRIM5 (Accession# LC727630) and human TRIM5α (Accession# LC727631) were aligned using the MUSCLE algorithm on MEGA X (MEGA Software). The parameters of alignment were as follows: gap open, − 2.90; gap extend, − 1.20; gap open penalty; 12, and gap extension penalty, 4.

To generate TRIM5-knockout MDBK cells, we designed five candidate sgRNAs for bovine TRIM5 on the website of CRISPRdirect (https://crispr.dbcls.jp/) (accessed on 4/4/2022). We used a Guide-it Complete sgRNA Screening System (TakaRa, Cat# Z2636N) to prepare sgRNAs targeting bovine TRIM5. Briefly, PCR was performed using PrimeSTAR Max Premix (2 ×), Guide-it Scaffold Template, and the following oligos: sgRNA #1 (5′-CCTCTTAATAGCCACTCATATAGGAAACAAAGAATCGCATAGTTAAGAGCTATGC-3′), sgRNA #2 (5′-CCTCTTAAATAGGCTATAGGAAACAAAGAATCGCATAGTTAAGAGCTATGC-3′), sgRNA #3 (5′-CCTCTTAAATAGGCTATAGGAAACAAAGAATCGCATAGTTAAGAGCTATGC-3′), sgRNA #4 (5′-CCTCTTAAATAGGCTATAGGAAACAAAGAATCGCATAGTTAAGAGCTATGC-3′), and sgRNA #5 (5′-CCTCTTAAATAGGCTATAGGAAACAAAGAATCGCATAGTTAAGAGCTATGC-3′). The PCR protocol consisted of 33 cycles of 98 °C for 10 s and 68 °C for 15 s for 10 s. Next, we mixed sgRNA PCR template, Guide-it In Vitro Transcription Buffer, Guide-it T7 Polymerase Mix, and RNase-free water to transcribe sgRNA from the PCR fragments. The PCR protocol was 35 °C for 4 h. After this reaction, recombinant DNase I (RNase-free) was added to the solution, which was incubated at 37 °C for 15 min. The transcribed sgRNA was purified with a column included in the kit. To test the in vitro cleavage efficiency of each sgRNA, genomic DNA was extracted from MDBK cells using DNeasy Blood & Tissue Kit (Qiagen, Cat# 69506). Next, we mixed 2 × Terra PCR Direct Buffer, forward primer (5′-AAATTATGGTTC TTGGGTTATCCTTT-3′), reverse primer (5′-TGAAATGCTACTCTGCTGAAGC-3′), Terra PCR Direct Polymerase Mix, RNase-free water, and genomic DNA of MDBK to amplify the target DNA. The PCR protocol was 98 °C for 2 min, 35 cycles of 98 °C for 10 s and 60 °C for 15 s, and 68 °C for 1 min. Then, the band was electrophoresed and purified using a QiAquick Gel Extraction Kit (Qiagen, Cat# 28706). Transcribed sgRNA and Guide-it Recombinant Cas9 Nuclease were mixed and incubated at 37 °C for 5 min. Next, the target DNA, 15 × Cas9 Reaction Buffer, 15 × BSA, and RNase-free water were mixed and incubated at 37 °C for 1 h. The reaction product was electrophoresed on a 1% agarose gel to visualize the cleaved bands.

Generation of TRIM5 knockout cells. Based on the result of the in vitro digestion assay, we generated a pSpCas9 (BB)-2A-Puro (PX459) V2.0 plasmid39 encoding sgRNA #4. We mixed these oligos: bT5a-4 (5′-ccgcGAGAGGCTTCGAGAAGTTA-3′), bT5a-4as (5′-aaacTAAACCTTGCGAGGCTTCGAGGTC-3′), and water and heated the mixture at 95 °C for 5 min, followed by incubation at room temperature for 1 h for oligo annealing. The mixture was 250-fold diluted with water and used for ligation with the PX459 V2.0 plasmid, which was predigested with BbsI-HF (NEB, Cat# R3539L). The solution was mixed with DNA Ligation Kit < Mighty Mix> (Takara, Cat# 6023) and used for transformation with NEB 5-alpha F’Iq Competent E. coli. After the miniprep, the nucleotide sequence of the plasmid was verified using a primer (5′-ACATCATATGCTTACG TAAC-3′).

The PX459-TRIM5-sgRNA#4 plasmid was used for transfection on MDBK cells using TransIT-T2 Dynamic Delivery System. MDBK cells were cultured for 2 weeks in the presence of 1 µg/mL puromycin (InvivoGen, Cat# B3593L). The cells were single-cell-cloned using a limiting dilution method. Each clone was characterized by viral infection and sequencing of genomic DNA as described previously.

Western blotting. The pelleted cells were lysed in 2 × Bolt LDS sample buffer (Thermo Fisher Scientific, Cat# B0008) containing 2% β-mercaptoethanol (Bio-Rad, Cat# 1610710) and incubated at 70 °C for 10 min. Expression level of HA-tagged TRIM5 in CRFK cells was confirmed by Western blotting using an anti-HA Tag (6E2) mouse mAb (HRP Conjugate) (CST, Cat# 2999S, × 5,000). After stripping the membrane using WB Stripping Solution Strong (Nacalai Tesque, Cat# 05677–65), the membrane was re-probed with an anti-β-Actin–HPR antibody (Sigma-Aldrich, Cat# A3854-200UL, × 20,000) as a loading control. Chemiluminescence was detected using Western BLoT Ultra Sensitive HRP Substrate (Takara, Cat# T7104A) according to the manufacturer’s instructions. Bands were visualized using an iBright FL1500 imaging system (Thermo Fisher Scientific), and the band intensity was quantified using iBright analysis software (Thermo Fisher Scientific).

Alignment of bovine TRIM5 and human TRIM5α proteins. The protein sequences of bovine TRIM5 (Accession# LC727630) and human TRIM5α (Accession# LC727631) were aligned using the MUSCLE algorithm on MEGA X (MEGA Software). The parameters of alignment were as follows: gap open, − 2.90; gap extend, 0.00; and hydrophobicity multiplier, 1.20.

Calculation of the identity between bovine TRIM5 and human TRIM5α proteins. The identity between bovine TRIM5 (Accession# LC727630) and human TRIM5α (Accession# LC727631) proteins was calculated on the website of SIM—Alignment Tool for protein sequences (https://web.expasy.org/simil/) (accessed on 7/11/2022). The parameters of calculation were as follows: comparison matrix, BLOSUM62; number of alignments computed, 20, gap open penalty; 12, and gap extension penalty, 4.
Statistical analysis. Differences in infectivity between two different conditions (e.g., between DMSO and Aphidicolin) were evaluated by an unpaired, two-tailed Student’s t-test. Differences in infectivity between WT, V86M, and H87Q were evaluated by one-way ANOVA, followed by the Tukey test. p ≤ 0.05 were considered statistically significant. These tests were performed using Prism 9 software v9.1.1 (GraphPad Software).

Data availability
The datasets generated and/or analysed during the current study are available in the GenBank (Accession# LC727630 for bovine TRIM5 mRNA isolated from MDBK cells, and LC727631 for human TRIM5α mRNA isolated from HeLa cells, respectively).

Received: 31 July 2022; Accepted: 21 September 2022 Published online: 18 October 2022

References
1. Lewis, P. F. & Emerman, M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68, 510–516 (1994).
2. Roe, T., Reynolds, T. C., Yu, G. & Brown, P. O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12, 2099–2108 (1993).
3. Lewis, P., Hensel, M. & Emerman, M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11, 3053–3058 (1992).
4. Zila, V. et al. Cone-shaped HIV-1 capsids are transported through intact nuclear pores. Cell 184, 1032–1046.e18 (2021).
5. Perry, C. & Rayat, A. C. M. E. Lentiviral vector bioprocessing. Viruses 13, 268 (2021).
6. Si, Z. et al. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc. Natl. Acad. Sci. USA 103, 7454–7459 (2006).
7. Ylinen, L. M. J. et al. Isolation of an active lsv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J. Virol. 80, 7332–7338 (2006).
8. Stremlau, M. et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427, 848–853 (2004).
9. Sayah, D. M., Sokolskaja, E., Berthoux, L. & Luban, J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430, 569–573 (2004).
10. Berthoux, L., Sebastian, S., Sokolskaja, E. & Luban, J. Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells. Proc. Natl. Acad. Sci. USA 102, 14849–14853 (2005).
11. Yap, M. W., Nisole, S., Lynch, C. & Stoye, J. P. Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. USA 101, 10774–10779 (2004).
12. Keckesova, Z., Ylinen, L. M. J. & Towers, G. J. The human and African green monkey TRIM5alpha genes encode Ref1 and lsv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA 101, 10780–10785 (2004).
13. Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S. & Bieniasz, P. D. Retrovirus resistance factors Ref1 and lsv1 are species-specific variants of TRIM5alpha. Proc. Natl. Acad. Sci. USA 101, 10774–10779 (2004).
14. Zhang, F., Hatziioannou, T., Perez-Caballero, D., Dene, D. & Bieniasz, P. D. Antiretroviral potential of human tripartite motif-5 and related proteins. Virolgy 353, 396–409 (2006).
15. Yamashita, M. & Engelman, A. N. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol. 25, 741–755 (2017).
16. Pacheco, B., Finzi, A., Stremlau, M. & Sodroski, J. Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5alpha. Virology 408, 204–212 (2010).
17. Soll, S. J., Wilson, S. J., Kutiayu, S. B., Hatziioannou, T. & Bieniasz, P. D. Assisted evolution enables HIV-1 to overcome a high TRIM5α-imposed genetic barrier to rhesus macaque tropism. PLoS Pathog. 9, e1003667 (2013).
18. Veillette, M. et al. The V86M mutation in HIV-1 capsid confers resistance to TRIM5alpha by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import. Retrovirology 10, 25 (2013).
19. Sayah, D. M., Sokolskaja, E., Berthoux, L. & Luban, J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430, 569–573 (2004).
20. Kim, K. et al. Cyclophilin A protects HIV-1 from restriction by human TRIM5α. Nat. Microbiol. 4, 2044–2051 (2019).
21. Sultana, T. et al. Multiple pathways to avoid beta interferon sensitivity of HIV-1 by mutations in capsid. J. Virol. 93, e00986-e0109 (2019).
22. Nisole, S., Lynch, C., Stoye, J. P. & Yap, M. W. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. USA 101, 13324–13328 (2004).
23. Sayah, D. M., Sokolskaja, E. & Luban, J. Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells. Proc. Natl. Acad. Sci. USA 102, 14849–14853 (2005).
37. McKay, T., Patel, M., Pickles, R. J., Johnson, L. G. & Olsen, J. C. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 13, 715–724 (2006).
38. Patel, M., Giddings, A. M., Sechelski, J. & Olsen, J. C. High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors. J. Gene Med. 15, 51–62 (2013).
39. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).

Acknowledgements
The following reagents were obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: SIV Packaging Construct (SIV3 +), ARP-13456, and SIV LTR Luciferase mCherry Reporter Vector, ARP-13455, both were contributed by Dr. Tom Hope. The following reagents were obtained through the Addgene: pLionII and pCRPDEnv were gifts from Garry Nolan. pMD2.G was a gift from Dr. Didier Trono. pEIAV-SIN6.1 CGFPW and pEV53D were gifts from Dr. John Olsen. pSptCas9(BB)-2A-Puro (PX459) V2.0 was a gift from Dr. Feng Zhang. The following plasmids were kind gifts from Dr. Kenzo Tokunaga: psPAX2-IN/HiBiT and pWPI-Luc2. The authors thank Dr. Tatsuo Shiota and Dr. Eri E. Nayakama for their continuous support. The authors thank Ms. Tomoko Nishiuchi and Dr. Shuya Mitoma for their assistance. This study was supported by the Frontier Science Research Center, University of Miyazaki. The authors would like to thank Enago (www.enago.com) for the English language review. Figure 2b was created with BioRender (https://biorender.com/).

Author contributions
N.M., E.P.B., Y.L.T., H.S., A.S. performed experiments. N.M. and A.S. designed experiments. N.M., T.O., H.M. and A.S. analysed results. N.M. and A.S. wrote manuscript. All authors read and approve the manuscript.

Funding
This work was supported by grants from the Japan Agency for Medical Research and Development (AMED) Research Program on HIV/AIDS JP21fk0410033, JP22fk0410033 and JP22fk0410047 (to A.S.); AMED Research Program on Emerging and Re-emerging Infectious Diseases JP20fk0108451 and JP21fk0108465 (to A.S.); AMED Japan Program for Infectious Diseases Research and Infrastructure JP21wm0325090 and JP22wm0325090 (to A.S.); AMED CRDF Global Grant JP21k0210039 and JP22k0210039 (to A.S.); from JSPS KAKENHI Grant-in-Aid for Scientific Research (C) 19K06382 (to A.S.); Grant-in-Aid for Scientific Research (B) 21H02361 (to T.O. and A.S.); Grant-in-Aid for Scientific Research (B) 22H02500 (to H.M. and A.S.); from The Ito Foundation Research Grant R4 (to A.S.) and from a Grant for Joint Research Projects of the Research Institute for Microbial Diseases, Osaka University (to A.S.).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-20970-6.

Correspondence and requests for materials should be addressed to A.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.